Cargando…

Genetic Alterations in Anaplastic Thyroid Carcinoma

INTRODUCTION: Anaplastic thyroid cancer (ATC) is rare but fatal thyroid cancer responsible for majority of thyroid cancer related mortality. ATC may originate de novo or from preexisting differentiated thyroid cancer. Complex interaction between different gene mutation has been suggested to be the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashid, M., Agarwal, Amit, Pradhan, Roma, George, Nelson, Kumari, Niraj, Sabaretnam, M, Chand, Gyan, Mishra, Anjali, Agarwal, Gaurav, Mishra, Saroj Kanta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844173/
https://www.ncbi.nlm.nih.gov/pubmed/31741910
http://dx.doi.org/10.4103/ijem.IJEM_321_19
_version_ 1783468384921321472
author Rashid, M.
Agarwal, Amit
Pradhan, Roma
George, Nelson
Kumari, Niraj
Sabaretnam, M
Chand, Gyan
Mishra, Anjali
Agarwal, Gaurav
Mishra, Saroj Kanta
author_facet Rashid, M.
Agarwal, Amit
Pradhan, Roma
George, Nelson
Kumari, Niraj
Sabaretnam, M
Chand, Gyan
Mishra, Anjali
Agarwal, Gaurav
Mishra, Saroj Kanta
author_sort Rashid, M.
collection PubMed
description INTRODUCTION: Anaplastic thyroid cancer (ATC) is rare but fatal thyroid cancer responsible for majority of thyroid cancer related mortality. ATC may originate de novo or from preexisting differentiated thyroid cancer. Complex interaction between different gene mutation has been suggested to be the main causative factor for origin of ATC in both pathways. Mostly affected pathways are MAP kinase and PI3CA kinase. Hence, we decided to study the frequent alterations in both the pathways in ATC patients. METHODOLOGY: Clinico-pathological data of 34 ATC patients were collected retrospectively and Formalin Fixed Paraffin Embedded (FFPE) blocks were taken out for genetic analysis. DNA and RANA were isolated from FFPE tissues. BRAF V600E mutations were screened by RFLP PCR method and confirmed by sequencing. RAS, PI3CA and p53 mutations were checked by sequencing. RET/PTC translocations were screened by Real Time PCR. RESULTS: A total of 34 patients were studied: Mean age 58.6+ 11.6 years with F:M- 1.8:1, 60% had history of goiter. Most common presenting symptom was rapidly growing thyroid mass followed by dyspnea, dysphasia and hoarseness of voice. Extent of disease was local, locoregional and metastatic in 32%, 35% and 33% respectively. 57.6% were euthyroid, 20.5 % were hyperthyroid while functional status were not available in 11.7%. FNAC was suggestive of ATC only in 52.9% cases. 15 (44%) were operated. BRAF V600E mutations were observed in 10/34 (29.4%). Interestingly, all three ATC patients with DTC components had previous history of goiter with rapid increase in size and BRAF V600E mutation, while BRAF was positive only in 7/31 (22.5%) of patients with no DTC component. Mean survival of 3.5 months in BRAF positive cases in comparison to 5.5 months in BRAF negative ATC. RAS mutations were found to be positive in 5.8%, and none had RET-PTC/PI3CA mutations. P53 mutation was positive in 7 patients. 3 patients presented with history of rapid increase in size of previous goiter while rest 4 patients presented with rapidly increasing thyroid swelling of 1 to 3 months. At presentation 2 patients has disease localized to thyroid, 4 has loco-regional disease and one patient presented with metastasis. 5 out of these 7 patients were operated (Total thyroidectomy:3, thyroidectomy with neck dissection:2). Mean survival was 4 months (1-6 months). CONCLUSION: BRAF V600E was the commonest mutation followed by p53 of the 5 genes tested and BRAF was more common in patients with previous history of longstanding goiter or differentiated thyroid cancer. This provides an indirect evidence of neoplastic transformation of PTC to ATC.
format Online
Article
Text
id pubmed-6844173
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-68441732019-11-18 Genetic Alterations in Anaplastic Thyroid Carcinoma Rashid, M. Agarwal, Amit Pradhan, Roma George, Nelson Kumari, Niraj Sabaretnam, M Chand, Gyan Mishra, Anjali Agarwal, Gaurav Mishra, Saroj Kanta Indian J Endocrinol Metab Original Article INTRODUCTION: Anaplastic thyroid cancer (ATC) is rare but fatal thyroid cancer responsible for majority of thyroid cancer related mortality. ATC may originate de novo or from preexisting differentiated thyroid cancer. Complex interaction between different gene mutation has been suggested to be the main causative factor for origin of ATC in both pathways. Mostly affected pathways are MAP kinase and PI3CA kinase. Hence, we decided to study the frequent alterations in both the pathways in ATC patients. METHODOLOGY: Clinico-pathological data of 34 ATC patients were collected retrospectively and Formalin Fixed Paraffin Embedded (FFPE) blocks were taken out for genetic analysis. DNA and RANA were isolated from FFPE tissues. BRAF V600E mutations were screened by RFLP PCR method and confirmed by sequencing. RAS, PI3CA and p53 mutations were checked by sequencing. RET/PTC translocations were screened by Real Time PCR. RESULTS: A total of 34 patients were studied: Mean age 58.6+ 11.6 years with F:M- 1.8:1, 60% had history of goiter. Most common presenting symptom was rapidly growing thyroid mass followed by dyspnea, dysphasia and hoarseness of voice. Extent of disease was local, locoregional and metastatic in 32%, 35% and 33% respectively. 57.6% were euthyroid, 20.5 % were hyperthyroid while functional status were not available in 11.7%. FNAC was suggestive of ATC only in 52.9% cases. 15 (44%) were operated. BRAF V600E mutations were observed in 10/34 (29.4%). Interestingly, all three ATC patients with DTC components had previous history of goiter with rapid increase in size and BRAF V600E mutation, while BRAF was positive only in 7/31 (22.5%) of patients with no DTC component. Mean survival of 3.5 months in BRAF positive cases in comparison to 5.5 months in BRAF negative ATC. RAS mutations were found to be positive in 5.8%, and none had RET-PTC/PI3CA mutations. P53 mutation was positive in 7 patients. 3 patients presented with history of rapid increase in size of previous goiter while rest 4 patients presented with rapidly increasing thyroid swelling of 1 to 3 months. At presentation 2 patients has disease localized to thyroid, 4 has loco-regional disease and one patient presented with metastasis. 5 out of these 7 patients were operated (Total thyroidectomy:3, thyroidectomy with neck dissection:2). Mean survival was 4 months (1-6 months). CONCLUSION: BRAF V600E was the commonest mutation followed by p53 of the 5 genes tested and BRAF was more common in patients with previous history of longstanding goiter or differentiated thyroid cancer. This provides an indirect evidence of neoplastic transformation of PTC to ATC. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6844173/ /pubmed/31741910 http://dx.doi.org/10.4103/ijem.IJEM_321_19 Text en Copyright: © 2019 Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Rashid, M.
Agarwal, Amit
Pradhan, Roma
George, Nelson
Kumari, Niraj
Sabaretnam, M
Chand, Gyan
Mishra, Anjali
Agarwal, Gaurav
Mishra, Saroj Kanta
Genetic Alterations in Anaplastic Thyroid Carcinoma
title Genetic Alterations in Anaplastic Thyroid Carcinoma
title_full Genetic Alterations in Anaplastic Thyroid Carcinoma
title_fullStr Genetic Alterations in Anaplastic Thyroid Carcinoma
title_full_unstemmed Genetic Alterations in Anaplastic Thyroid Carcinoma
title_short Genetic Alterations in Anaplastic Thyroid Carcinoma
title_sort genetic alterations in anaplastic thyroid carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844173/
https://www.ncbi.nlm.nih.gov/pubmed/31741910
http://dx.doi.org/10.4103/ijem.IJEM_321_19
work_keys_str_mv AT rashidm geneticalterationsinanaplasticthyroidcarcinoma
AT agarwalamit geneticalterationsinanaplasticthyroidcarcinoma
AT pradhanroma geneticalterationsinanaplasticthyroidcarcinoma
AT georgenelson geneticalterationsinanaplasticthyroidcarcinoma
AT kumariniraj geneticalterationsinanaplasticthyroidcarcinoma
AT sabaretnamm geneticalterationsinanaplasticthyroidcarcinoma
AT chandgyan geneticalterationsinanaplasticthyroidcarcinoma
AT mishraanjali geneticalterationsinanaplasticthyroidcarcinoma
AT agarwalgaurav geneticalterationsinanaplasticthyroidcarcinoma
AT mishrasarojkanta geneticalterationsinanaplasticthyroidcarcinoma